431 related articles for article (PubMed ID: 27287891)
21. Graphene-Based Smart Platforms for Combined Cancer Therapy.
Gu Z; Zhu S; Yan L; Zhao F; Zhao Y
Adv Mater; 2019 Mar; 31(9):e1800662. PubMed ID: 30039878
[TBL] [Abstract][Full Text] [Related]
22. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
Linton SS; Sherwood SG; Drews KC; Kester M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):208-22. PubMed ID: 26153136
[TBL] [Abstract][Full Text] [Related]
23. Polymer conjugates as anticancer nanomedicines.
Duncan R
Nat Rev Cancer; 2006 Sep; 6(9):688-701. PubMed ID: 16900224
[TBL] [Abstract][Full Text] [Related]
24. Nucleic acid nanotechnology for cancer treatment.
Jin JO; Kim G; Hwang J; Han KH; Kwak M; Lee PCW
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188377. PubMed ID: 32418899
[TBL] [Abstract][Full Text] [Related]
25. Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions.
Raj R; Mongia P; Kumar Sahu S; Ram A
Curr Drug Targets; 2016; 17(2):206-28. PubMed ID: 26201484
[TBL] [Abstract][Full Text] [Related]
26. Programmable nanomedicine: synergistic and sequential drug delivery systems.
Pacardo DB; Ligler FS; Gu Z
Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
[TBL] [Abstract][Full Text] [Related]
27. Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.
Banudevi S; Swaminathan S; Maheswari KU
Nutr Cancer; 2015; 67(7):1021-48. PubMed ID: 26359767
[TBL] [Abstract][Full Text] [Related]
28. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
Sun D; Chen J; Wang Y; Ji H; Peng R; Jin L; Wu W
Theranostics; 2019; 9(23):6885-6900. PubMed ID: 31660075
[TBL] [Abstract][Full Text] [Related]
29. Design of multifunctional nanocarriers for delivery of anti-cancer therapy.
Mehra NK; Jain K; Jain NK
Curr Pharm Des; 2015; 21(42):6157-64. PubMed ID: 26503145
[TBL] [Abstract][Full Text] [Related]
30. The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics.
Deng Y; Zhang H
Int J Nanomedicine; 2013; 8():1835-41. PubMed ID: 23674895
[TBL] [Abstract][Full Text] [Related]
31. Graphene as multifunctional delivery platform in cancer therapy.
Nejabat M; Charbgoo F; Ramezani M
J Biomed Mater Res A; 2017 Aug; 105(8):2355-2367. PubMed ID: 28371194
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives.
Thambi T; Park JH; Lee DS
Chem Commun (Camb); 2016 Jun; 52(55):8492-500. PubMed ID: 27225824
[TBL] [Abstract][Full Text] [Related]
33. Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review.
Fathi-Karkan S; Arshad R; Rahdar A; Ramezani A; Behzadmehr R; Ghotekar S; Pandey S
Eur J Med Chem; 2023 Nov; 259():115676. PubMed ID: 37499287
[TBL] [Abstract][Full Text] [Related]
34. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
35. Nanoformulation-based sequential combination cancer therapy.
Shim G; Kim MG; Kim D; Park JY; Oh YK
Adv Drug Deliv Rev; 2017 Jun; 115():57-81. PubMed ID: 28412324
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
37. Cancer nanomedicine: from targeted delivery to combination therapy.
Xu X; Ho W; Zhang X; Bertrand N; Farokhzad O
Trends Mol Med; 2015 Apr; 21(4):223-32. PubMed ID: 25656384
[TBL] [Abstract][Full Text] [Related]
38. Nano based drug delivery systems: recent developments and future prospects.
Patra JK; Das G; Fraceto LF; Campos EVR; Rodriguez-Torres MDP; Acosta-Torres LS; Diaz-Torres LA; Grillo R; Swamy MK; Sharma S; Habtemariam S; Shin HS
J Nanobiotechnology; 2018 Sep; 16(1):71. PubMed ID: 30231877
[TBL] [Abstract][Full Text] [Related]
39. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.
Juliano RL; Alam R; Dixit V; Kang HM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(3):324-35. PubMed ID: 20049800
[TBL] [Abstract][Full Text] [Related]
40. Platelet membrane-based and tumor-associated platelettargeted drug delivery systems for cancer therapy.
Zhang Y; Liu G; Wei J; Nie G
Front Med; 2018 Dec; 12(6):667-677. PubMed ID: 29619757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
